The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.

Sanofi and GSK are way behind in the COVID-19 vaccine race and the start of a rolling review of Vizprevtyn at the European Medicines Agency is an important step.

Sanofi is beefing up its investment in mRNA vaccine technology with a €400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.

New long-term Phase III data for Takeda's candidate dengue vaccine show continued protection against illness and hospitalization, regardless of previous exposure, out to the three-year mark following the two-dose jab.